ARTIVION, INC.
Close on Oct 19, 2026
- Market cap
- $1.08B
- P/E (TTM)
- –
- Dividend yield
- –
About Artivion
Surgical & Medical Instruments & Apparatus, SIC 3841
Artivion, Inc. manufactures, processes, and distributes medical devices and implantable human tissues for patients suffering from aortic diseases. The company operates through two primary reportable segments: Medical Devices and Preservation Services. Its medical device offerings include aortic stent grafts, mechanical heart valves, surgical sealants, and related surgical tools. Through its preservation services, the company cryopreserves and supplies human cardiac and vascular donor tissues. Its offerings are primarily used by cardiac and vascular surgeons treating aortic aneurysms, dissections, and heart valve conditions.
The company maintains a global commercial presence, distributing products across North America, Latin America, the Asia-Pacific region, Europe, the Middle East, and Africa. Its operational footprint includes key subsidiaries based in Hechingen, Germany, and Austin, Texas, alongside approximately twenty regional corporate entities dedicated to international sales and marketing operations. The provided text does not state the location of the company's corporate headquarters.
Summary of the business section of Artivion's latest annual report, written by StockData.
Company profile
Company
- Legal name
- ARTIVION, INC.
- Founded
- 1984
- Headquarters
- Kennesaw, GA
- Address
- 1655 Roberts Boulevard N W 30144
- Phone
- (770) 419-3355
- Website
- www.cryolife.com
- Employees
- 1,800, Dec 31, 2025
- Industry
- Surgical & Medical Instruments & Apparatus
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Ernst & Young LLP, Atlanta, Georgia
Stock & identifiers
- Ticker
- AORT
- Exchange
- NYSE
- Shares outstanding
- 49M, Jul 31, 2026
- Public float
- $1.39B, Jun 30, 2025
- Filer category
- Large accelerated filer
- Stock splits
- 3-for-2, Dec 28, 2000; 2-for-1, Jul 1, 1996
- SEC CIK
- 784199
- CUSIP
- 228903100
- ISIN
- US2289031005
- LEI
- 549300YTKV8DMSMG6K81
- EIN
- 59-2417093
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Andrew M. Green | SVP, Regulatory and Quality | 40,160 |
| James P. Mackin | President & CEO | 877,275 |
| Lance A. Berry | EVP, COO, CFO & Treasurer | 210,112 |
| Jean F. Holloway | SVP, General Counsel | 184,118 |
| Amy Horton | VP, Chief Accounting Officer | 139,088 |
| John E. Davis | Chief Commercial Officer | 230,794 |
| Marshall S. Stanton | SVP, Clinical & MD Affair | 60,097 |
| Anthony B. Semedo | Director | 47,560 |
| James Bullock | Director | 76,223 |
| Jeffrey H. Burbank | Director | 61,372 |
| Marna P. Borgstrom | Director | 56,664 |
| Elizabeth A. Hoff | Director | 34,765 |
| Daniel J. Bevevino | Director | 157,637 |
| Thomas F. Ackerman | Director | 157,472 |
| Jon W. Salveson | Director | 137,416 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Mr. Mackin | $6.88M | $17.44M | $2.13M | $193 | $127 |
| FY2024 Mr. Mackin | $5.51M | $12.33M | $1.70M | $121 | $117 |
| FY2023 Mr. Mackin | $3.18M | $7.23M | $1.20M | $76 | $106 |
| FY2022 Mr. Mackin | $7.22M | $4.72M | $1.80M | $51 | $97 |
| FY2021 Mr. Mackin | $4.63M | $3.71M | $1.29M | $86 | $119 |
| FY2020 Mr. Mackin | $3.42M | $327.65K | $977.09K | $87 | $118 |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of December 31, 2025 we had approximately 1,800 employees.”
Corporate history
Events identified from SEC filings